Details of the Drug

General Information of Drug (ID: DM83SEB)

Drug Name
Faricimab
Synonyms RO6867461; RG7716
Indication
Disease Entry ICD 11 Status REF
Diabetic macular edema 9B71.02 Approved [1]
Neovascular age-related macular degeneration 9B78.3Z Approved [1]
Affected Organisms
Humans and other mammals
ATC Code
S01LA09: Faricimab
S01LA: Antineovascularisation agents
S01L: OCULAR VASCULAR DISORDER AGENTS
S01: OPHTHALMOLOGICALS
S: SENSORY ORGANS
Drug Type
Antibody
Cross-matching ID
UNII
QC4F7FKK7I
DrugBank ID
DB15303
TTD ID
D9MWL4

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiopoietin-2 (ANGPT2) TTKLQTJ ANGP2_HUMAN Not Available [2]
Vascular endothelial growth factor A (VEGFA) TTOHSBA VEGFA_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Diabetic macular edema
ICD Disease Classification 9B71.02
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor A (VEGFA) DTT VEGFA 3.61E-01 0.15 0.47
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761235.
2 Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.